IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: Susan W. BARNETT et al.

Application No.: 09/475,704

Filing Date: December 30, 1999

For: POLYNUCLEOTIDES ENCODING

ANTIGENIC HIV TYPE C

POLYPEPTIDES, POLYPEPTIDES AND

USES THEREOF

Examiner: J. S. Pitrak

Group Art Unit: 1635

Confirmation No.: 6738

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97 & § 1.98

MAIL STOP: AMENDMENT Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. §1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO/SB/08a/b. Copies of foreign documents and non-patent literature are submitted herewith. The Examiner is requested to make these documents of record.

Applicants would like to bring to the Examiner's attention the fact that:

 An English abstract of foreign-language document 6 listed on the attached Form PTO/SB/08a/b is included.

	This Supplemental Information Disclosure Statement is submitted:
	With the application; accordingly, no fee or separate requirements are required.
	Before the mailing of a first Office Action after the filing of a Request for Continued
	Examination under 37 C.F.R. § 1.114. However, if applicable, a certification under 37
	C.F.R. § 1.97 (e)(1) has been provided.
	Within three months of the application filing date or before mailing of a first Office Action
	on the merits; accordingly, no fee or separate requirements are required. However, if
	applicable, a certification under 37 C.F.R. § 1.97 (e)(1) has been provided.
\boxtimes	After receipt of a first Office Action on the merits but before mailing of a final Office
	Action or Notice of Allowance.
	submission.
	A Certification under 37 C.F.R. § 1.97(e) is provided above; accordingly; no fee in
	believed to be due.
	After mailing of a final Office Action or Notice of Allowance, but before payment of the
	Issue Fee.
	A Certification under 37 C.F.R. § 1.97(e) is provided above and a Fee Transmitta
	Form (PTO/SB/17) is attached to this submission.)
	Applicants would appreciate the Examiner initialing and returning the Form
PTO	B/08a/b, indicating that the information has been considered and made of record herein.

The information contained in this Supplemental Information Disclosure Statement under 37 C.F.R. § 1.97 and § 1.98 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist;

(iii) the information, protocols, results and the like reported by third parties are accurate or enabling;

or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal form is separated from this document and the Patent and Trademark Office determines that an extension and/or other relief (such as payment of a fee under 37 C.F.R. § 1.17 (p)) is required, Applicants petition for any required relief including

Novartis Docket No. PAT051386-US-NP Docket No. 223002109700

Application No. 09/475,704

3

extensions of time and authorize the Commissioner to charge the cost of such petition and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing **223002109700**.

Dated: June 4, 2010 Respectfully submitted,

By /Otis Littlefield/ Otis B. Littlefield

Registration No.: 48,751

MORRISON & FOERSTER LLP 425 Market Street San Francisco, California 94105-2482 Telephone: 415.268.6846

Fax: 415.268.7522